Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research. Welcome Guest login/register     0 items 

  Home | My Account | Customer Service | About Us

US:
Int'l:
 800-298-5699
 +1-212-807-2600


Quick Search

  

Advanced Search  

Research Assistance
Send us a request

 
Matching Categories
This report can be found in:

Therapeutic Area

   Behavioral Health




 
Sign up today for free email alerts of new market research reports in your industry.
 



  Home > Back to Publisher > Report Information   Email a Colleague | Printer Format    

Strategic Perspectives: Commercial Opportunites in Depression - Generating Revenue Growth In Symptoms And Comorbidities

Datamonitor

January 7, 2003

148 Pages - Pub ID: DFMN855868
Questions About This Report?

Order by Fax

XE.com
Abstract   Table of Contents   Search Inside
This Report
  Related Products  

Countries covered: Japan, France, Germany, Italy, Spain, United Kingdom, United States


 
Introduction:The growth of the antidepressant market over the last decade has been built upon increasingly sophisticated marketing strategies. This has not only made the depression market highly competitive, but also produced an expanded patient potential as manufacturers move their products into non-traditional markets. Scope: * Analysis of depressive symptoms in presenting patients from the seven major markets * Analysis of depressive symptoms throughout the course of the illness in treated patients from the seven major markets * The level of comorbidity of anxiety and non-anxiety disorders in treated depression patients from the seven major markets * Analysis of the leading products in each of these areas of the depression market * Datamonitorís strategic recommendations for marketed and pipeline drugs. Report Highlights: Traditionally, manufacturers have sought indications in anxiety disorders to ensure product growth. However, following the licensing of fluoxetine for bulimia and bupropion for smoking cessation, Datamonitor has identified a third phase of potential development for antidepressant drugs. By targeting non-anxiety disorders, manufacturers are continually escalating the patient potential for their drugs, which is crucial if the rapid expansion of the antidepressant is to be continued in this decade.The understanding of the prevalence level of depressive symptoms, both at presentation and throughout the illness, is key for all antidepressant manufacturers to devise successful marketing strategies. Furthermore, the competitive landscape in these sub-markets is crucial to understand, if a significant return on investment is to be achieved.Reasons to Purchase: * Understand the prevalence level of depressive symptoms in the treated population * Enhance your understanding of how these symptoms respond to current therapies * Identify the prevalence level of specific anxiety disorders in the treated depression population * Increase your understanding of the prevalence level of non-anxiety disorders in depression patients * Discover the commercial and strategic opportunities that exist in these areas of the depression market



 

 Home   |   My Account   |   Customer Service   |   About Us   |   Press   |   Help FAQs 
     Privacy Policy   |   Terms and Conditions   |   Site Map   |   Return Policy         

Contact Us: 800-298-5699 (U.S.) or +1-212-807-2600 (Int'l)
Hours: 8:30am to 7:00pm EST Monday thru Thursday and 8:30am to 6:30pm EST Friday

Copyright © 1999-2003, All Rights Reserved, MarketResearch.com
1/8/2004 - 1